Showing results (301-310 of 336) with videos related to
Sort By:
Pageof 34
JTO Clinical and Research Reports|August 2, 2024
Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAILShigehiro Yagishita, Yasushi Goto, Makoto Nishio, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2025
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung CancerMark M Awad, Patrick M Forde, Nicolas Girard, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2011
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohortSeiji Yano, Tadaaki Yamada, Shinji Takeuchi, et al.Lung Cancer (Amsterdam, Netherlands)|November 21, 2024
Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancerHiroaki Akamatsu, Yasuhiro Koh, Makoto Nishio, et al.Lancet (London, England)|May 15, 2017
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trialToyoaki Hida, Hiroshi Nokihara, Masashi Kondo, et al.The Lancet. Oncology|October 19, 2016
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 studyGlenwood Goss, Chun-Ming Tsai, Frances A Shepherd, et al.Science (New York, N.Y.)|April 28, 2007
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingJeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, et al.Lung Cancer (Amsterdam, Netherlands)|December 9, 2019
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancerKazuhiko Nakagawa, Toyoaki Hida, Hiroshi Nokihara, et al.The Oncologist|December 16, 2020
Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid TumorsMasayuki Takeda, Takayuki Takahama, Kazuko Sakai, et al.International Journal of Clinical Oncology|May 27, 2026
Quantitative evaluation of healthcare information provided to patients with thoracic malignancies: patient satisfaction survey of the Japan Lung Cancer SocietyTakayuki Takahama, Hidefumi Shimizu, Kenichi Yoshimura, et al.Pageof 34